A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

被引：0
|
作者：
Pavel, M. E. [1 ]
Ferone, D. [2 ]
Halperin, D. [3 ]
Myrehaug, S. [4 ]
Herrmann, K. [5 ,6 ]
Kunz, P. L. [7 ]
Chasen, B. [8 ]
Castillon, J. Capdevila [9 ]
Tafuto, S. [10 ]
Oh, D-Y. [11 ]
Yoo, C. [12 ]
Falk, S. [13 ]
Halfdanarson, T. R. [14 ]
Folitar, I. [15 ]
Zhang, Y. [16 ]
de Herder, W. W. [17 ]
Singh, S. [4 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nuernberg, Uniklinikum Erlangen, Dept Med 1, Erlangen, Germany
[2] Univ Genoa, IRCCS Policlin San Martino & DiMI, Endocrinol, Genoa, Italy
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA
[4] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[6] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[7] Yale Univ, Yale Sch Med, New Haven, CT USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Div Diagnost Imaging, Houston, TX 77030 USA
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Oncol Clin & Sperimentale Sarcomi & Tumori Rari, Naples, Italy
[11] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea
[12] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[13] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, Avon, England
[14] Mayo Clin, Div Med Oncol, Rochester, MN USA
[15] Novartis Pharma AG, Clin Dev, Basel, Switzerland
[16] Novartis Pharmaceut, Biostat, E Hanover, NJ USA
[17] Erasmus MC, Internal Med, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1148MO
引用
收藏
页码：S753 / S753
页数：1
相关论文
共 50 条
  • [41] The Phase 3 NETTER-1 Study of [177Lu]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety
    Kunz, P.
    Caplin, M. E.
    Ruszniewski, P. B.
    Bodei, L.
    Hendifar, A.
    Mittra, E.
    Wolin, E. M.
    Yao, J. C.
    Pavel, M. E.
    Grande, E.
    Van Cutsem, E.
    Seregni, E.
    Duarte, H.
    Demange, A.
    Mutevelic, S.
    Strosberg, J. R.
    Krenning, E. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S188 - S188
  • [42] Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE
    Bruvoll, Ragnar
    Blakkisrud, Johan
    Mikalsen, Lars Tore
    Connelly, James
    Stokke, Caroline
    CANCERS, 2023, 15 (04)
  • [43] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Johannes Zellmer
    Hsi-Yu Yen
    Lena Kaiser
    Erik Mille
    Franz Josef Gildehaus
    Guido Böning
    Katja Steiger
    Marcus Hacker
    Peter Bartenstein
    Andrei Todica
    Alexander R. Haug
    Harun Ilhan
    EJNMMI Research, 10
  • [44] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Zellmer, Johannes
    Yen, Hsi-Yu
    Kaiser, Lena
    Mille, Erik
    Gildehaus, Franz Josef
    Boening, Guido
    Steiger, Katja
    Hacker, Marcus
    Bartenstein, Peter
    Todica, Andrei
    Haug, Alexander R.
    Ilhan, Harun
    EJNMMI RESEARCH, 2020, 10 (01)
  • [45] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [46] Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs
    Kapidzic, Selma Curkic
    Gustafsson, Johan
    Larsson, Erik
    Jessen, Lovisa
    Gleisner, Katarina Sjogreen
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2024, 120
  • [47] [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study
    Singh, Simron
    Halperin, Daniel M.
    Myrehaug, Sten
    Herrmann, Ken
    Pavel, Marianne
    Kunz, Pamela L.
    Chasen, Beth
    Capdevila, Jaume
    Tafuto, Salvatore
    Oh, Do-Youn
    Yoo, Changhoon
    Falk, Stephen
    Halfdanarson, Thorvardur Ragnar
    Folitar, Ilya
    Zhang, Yufen
    Santoro, Paola
    Aimone, Paola
    de Herder, Wouter W.
    Ferone, Diego
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA588 - LBA588
  • [48] In house labeling and characterization of 177Lu DOTA-TATE
    Yadav, Alok Kumar
    Meera, V
    Banerjee, Sharmila
    Malhotra, A.
    Bal, Chandarsekhar
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [49] Efficacy, Toxicity, and Prognostic Factors of Re- treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center
    Silva, Maria Manuel
    Canha, Marta
    Salazar, Daniela
    Neves, Joao Sergio
    Ferreira, Goncalo
    Carvalho, Davide
    Duarte, Hugo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [50] [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomised NETTER-2 study
    de Herder, W. W.
    Halperin, D.
    Myrehaug, S.
    Herrmann, K.
    Pavel, M.
    Kunz, P. L.
    Chasen, B.
    Capdevila, J.
    Tafuto, S.
    Oh, D. Y.
    Yoo, C.
    Falk, S.
    Halfdanarson, T.
    Folitar, I
    Zhang, Y.
    Santoro, P.
    Aimone, P.
    Ferone, D.
    Singh, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 203 - 203
12345